The present study was performed to investigate the ability of the multidrug resistance protein (MRP1) to transport different cationic substrates in comparison with MDR1-Pglycoprotein (MDR1). Transport studies were performed with isolated membrane vesicles from in vitro selected multidrug resistant cell lines overexpressing MDR1 (A2780AD) or MRP1 (GLC 4 /Adr) and a MRP1-transfected cell line (S1(MRP)). As substrates we used [
Introduction
Human multidrug resistance is frequently associated with the overexpression of the MDR1-P-glycoprotein (MDR1) 1 and/or the multidrug resistance protein (MRP1), 2 two members of the ATP binding cassette (ABC) transporter superfamily. 3 Although they share only 15% amino acid sequence homology, both proteins confer resistance to a broad range of natural product drugs in drug selected cell lines as well as in transfected cells. [4] [5] [6] Currently, it is generally accepted that MDR1 functions as an ATP-dependent transport protein capable of reducing intracellular levels of various natural product drugs. [7] [8] [9] Most of these drugs, e.g. vinca alkaloids, anthracyclines, epipodophillotoxins, actinomycin D and paclitaxel, have unrelated chemical structures but share the property of being hydrophobic compounds.
MRP1 was first identified in tumour cells with a multidrug resistant phenotype without overexpression of MDR1. 2 Although MRP1 is able to confer resistance to drugs which are MDR1 substrates, the substrate specificity of MRP1 seems different from that of MDR1. Transport studies with membrane vesicles isolated from MRP1 overexpressing cells, either in vitro selected or transfected, revealed that MRP1 is a transporter of multivalent organic anions, preferentially glutathione S-conjugates (GS S-conjugates), [10] [11] [12] [13] [14] but also of sulphate conjugates 12 and glucuronides. 12, 15 Also oxidized glutathione (GSSG), complexes of reduced glutathione (GSH) with arsenite 16 and unmodified compounds in the presence of GSH 11, 13 are MRP1 substrates. In view of its substrate specificity and the ubiquitous expression of MRP1 in human tissues 17 and blood cells, 18 the putative physiological role of MRP1 seems to be cellular extrusion of metabolites of GSH-dependent detoxification reactions. 19 The molecular basis of the drug specificity of MRP1 is not fully understood. Two models currently exist describing the drug transport mechanism of MRP1. First, MRP1 may be a transporter of drug conjugates (e.g. GS S-conjugates and glucuronide conjugates), 20, 12, 21 however, stable GS S-conjugates of vincristine and daunorubicin could not be detected in HPLC-analyzed media from MRP1 transfected cells. 16 Moreover, there is no evidence that the chemotherapeutic agents to which MRP1 confers resistance, are substrates for GSH-or glucuronic acid conjugation (for review see ref. 22, 23) . Secondly, MRP1 may transport unmodified natural product drugs in the presence of GSH. For example, it has been demonstrated that unmodified vincristine is transported by MRP1 but only in the presence of physiological concentrations of GSH. 13 Furthermore, resistance to vinca alkaloids and anthracyclines is reversed by GSH depletion in MRP1-overexpressing cells, but not in cells overexpressing MDR1. 16, 24 Therefore, GSH appears to play an important role in MRP1-mediated drug resistance. In this study we compared MDR1 and MRP1 with respect to their ability to transport different classes of cationic drugs and investigated the role of GSH in MRP1-mediated transport. We hypothesized that the hydrophobic basic drug daunorubicin has not necessarily to be conjugated with GSH to be a MRP1 substrate, 20, 21 but is transported by MRP1 in the presence of GSH. We used vincristine as a previously demonstrated MRP1 substrate 13 to characterise our experimental system. Furthermore, experiments were performed with the permanently positively charged monoquaternary cationic derivate of the anti-arrhythmic drug ajmaline (N-(4',4'-azo-n-pentyl)-21-deoxy-ajmalinium, APDA) to study the ability of MRP1 to mediate the transport of more hydrophilic cations which are excellent MDR1 substrates in vitro. 
Material en methods

Chemicals
Cell culture
Culture procedures for the human GLC 4 small cell lung cancer line and its doxorubicin selected multidrug resistant counterpart GLC 4 /Adr have been described previously. 26 Culture of the non-small cell lung cancer cell line SW1573/S1, further designated as S1, and of its MRP1 transfected subline S1(MRP) was performed as reported 27 only with stepwise increase of the Geneticin concentration to 0.4 mg ml -1 , Life Technologies (Paisley, UK). The human ovarian tumour cell line A2780 was cultured in RPMI1640 medium, supplemented with 10% foetal calf serum (FCS), (Life Technologies). The multidrug resistant A2780AD line was isolated from the A2780 line by a multistep selection with doxorubicin and maintained in RPMI1640 medium supplemented with 10% FCS as described.
28
Preparation of membrane vesicles
Membrane vesicles were prepared as described previously 14 with minor modifications. Briefly, cells were harvested, washed with phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10.1 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , pH 7.4) and centrifuged at 180 x g, for 10 min at 4°C. The resulting pellet was diluted 40-fold in hypotonic buffer (1 mM NaHCO 3 , pH 7.4) and stirred gently in the presence of 100 U Benzonase for 1 h. The cell lysate was centrifuged at 100,000 x g for 30 min at 4°C and the remaining pellet was resuspended in 5 ml isotonic TS buffer (10 mM Tris/250 mM sucrose, pH 7.4) and homogenized with a Dounce B homogenizer in the presence of 100 U Benzonase. The crude membrane fraction was layered on top of a 38% (w/v) sucrose solution in 10 mM Tris (pH 7.4) and centrifuged at 280,000 x g for 1 h at 4°C in a swing out rotor. The interface layer was collected, diluted to 25 ml in TS buffer and centrifuged at 100,000 x g for 30 min at 4°C. The resulting pellet was resuspended in 300-500 µl isotonic buffer. Vesicles were formed by passing the suspension 20 times through a 25 gauge needle. The membrane vesicles were snap frozen in liquid nitrogen and stored at -80°C. Protein content was measured by a Bradford-based Biorad protein assay (Biorad laboratories, Hercules, CA).
Immunodetection of MRP1 and MDR1
Ten µg protein of each membrane preparation was separated on a SDS/7.5% polyacrylamide gel and transferred to nitrocellulose (Amersham) by electroblotting. MRP1 was detected by the rat monoclonal MRPr1 (1:500), kindly provided by Dr. R. Scheper, (Free University, Amsterdam, the Netherlands). MDR1 was detected by the monoclonal antibody C219 (1:500), (Centocor, Malvern, MA, USA). MRP2 protein levels were analyzed with the monoclonal antibody M 2 III-5, a kind gift of Dr. R. Oude Elferink (Academic Medical Centre, Amsterdam, the Netherlands). Primary antibodies were visualized by enhanced chemiluminescence (ECL), (Pierce, Rockford, IL, USA). 
MDR1-Pgp
Transport studies Uptake of [
3 H]APDA (300 nM), [ 3 H]vincristine (300 nM) and [ 3 H]daunorubicin (600 nM) into membrane vesicles was measured by a rapid filtration technique. Membrane vesicles (50 µg protein) were rapidly thawed and added to the buffer system containing 4 mM ATP or AMP-PCP, 10 mM MgCl 2 , 10 mM creatine phosphate, 100 µg ml -1 creatine kinase, 10 mM Tris pH 7.4 and 250 mM sucrose. After 1 min prewarming at 37°C, the substrate was added (110 µl final volume). At indicated time points, samples (25 µl) were taken and diluted in 1 ml ice cold stopsolution (PBS). These solutions were subsequently filtered through OE66 cellulose acetate filters, pore size 0.2 µm (Schleicher & Schuell, Dassel, Germany), presoaked in PBS. Filters were rinsed with 5 ml PBS/0.05% Tween 20 followed by 5 ml PBS. After rinsing, the filters were air dried and radioactivity was counted with a liquid scintillation counter. Experiments with [ 3 H]daunorubicin were performed similarly, except that the PBS stopsolution contained 1 mM ethidium bromide, the filters were presoaked in PBS/1 mM ethidium bromide and the filters were first washed by 5 ml PBS/1 mM ethidium bromide, followed by PBS/0.05% Tween 20 and 5 ml PBS. This method reduced the background binding of Uptake experiments in the presence of the MRP1-specific monoclonal antibody (mAb) QCRL-3 or the control mAb directed against the T-cell marker CD3 (a kind gift of Dr. B.J. Kroesen, University Hospital Groningen) were performed for 1 min as described above. The mAbs were added together with the membrane vesicles to the buffer system.
All transport data are presented as the difference of the values measured in the presence of ATP and in the presence of AMP-PCP. The non-hydrolyzable ATP analogue AMP-PCP did not support uptake, demonstrating that ATP hydrolysis was required.
Results
Immunoblot analysis of MRP1 and MDR1
The levels of MRP1 and MDR1 in membrane subfractions were analyzed by immunoblotting. Increased levels of the 190 kDa MRP1 14, 29 were detected in membranes from GLC 4 /Adr and MRP1-transfected S1(MRP) cells, while membranes isolated from A2780, A2780AD, GLC 4 and S1 cells exhibited lower levels (Figure 1 ). MDR1 was found to be overexpressed in membranes isolated from A2780AD cells. No expression of MDR1 was found in membrane preparations from the other cell lines. MRP2 was not detected in membranes from any of these cell lines (data not shown). ATP-dependent uptake of all three substrates into A2780AD membrane vesicles was increased compared to A2780 membrane vesicles. This uptake was inhibited by the MDR1 inhibitor PSC833. These results indicate that the ATP-dependent transport of Under the same conditions, transport studies were performed with membrane vesicles from GLC 4 cells and the MRP1-overexpressing GLC 4 /Adr cell line ( Figure  2b ). The cysteinyl-leukotriene LTC 4 Figure 2b ) might be driven by a proton gradient. To eliminate this uptake we used the vacuolar H + -ATPase (V-type ATPase) inhibitor bafilomycin A 1 (Baf) to block the potential involvement of proton gradient generating V-type ATPases. (Figure 1 ). These data show that MRP1-mediated ATP-dependent transport of daunorubicin appears to be GSH-dependent. To gain more insight into the initial uptake phase, a 2 min time course of [ 3 H]daunorubicin uptake was measured (Figure 4 ). Because of a relatively low overexpression of MRP1 in S1(MRP) membrane vesicles, GLC 4 /Adr membrane vesicles were used for these experiments. In the presence of 5 mM GSH, the uptake of 
ATP-dependent uptake of cationic drugs in membrane vesicles from MDR1-and MRP1-overexpressing cells
Dependency of MRP1-mediated daunorubicin transport on GSH concentration
The effect of different GSH concentrations on MRP1-mediated daunorubicin transport was investigated with GLC 4 /Adr membrane vesicles. Figure 6 shows that [ 3 H]daunorubicin transport was stimulated by increased concentrations of GSH with a maximum of 10 mM after which a steady state level was reached. The K m value was determined to be 2.7 mM. 
Discussion
MDR1 and MRP1, two distantly related members of the large superfamily of ABCtransporter proteins, are both able to confer resistance of cells against a broad spectrum of natural product drugs. [4] [5] [6] MDR1-related multidrug resistance is most likely due to the ATP-dependent extrusion of unmodified drugs from the cells mediated by the MDR1 protein. [31] [32] [33] [34] [35] [36] Also MRP1-mediated multidrug resistance depends on the transport capacity of MRP1, but the mechanism by which this protein mediates drug transport appears to differ from MDR1. Most MRP1 substrates are organic compounds that need to be conjugated with e.g. GSH before being transported. Also some organic cationic drugs appear to be MRP1 substrates. Although these substrates are not known to form GS S-conjugates, it has been shown that the presence of GSH is required for MRP1-associated resistance against the cytotoxicity of these drugs. 24, 16 This suggests that for MRP1-mediated extrusion of these cations, GSH is required without a need for conjugation. This prompted us to investigate the role of GSH in MRP1-mediated organic cation transport. 40, 41 This is a clear indication that MRP1, in contrast to MDR1, is not directly involved in ATP-dependent transport of these cationic substrates. We have recently demonstrated that GLC 4 /Adr cells have a more pronounced Golgi apparatus and contain more intracellular vesicular structures than GLC 4 cells. 42 We therefore speculated that addition of ATP might activate V-type ATPases that are present in membranes of certain intracellular organelles. These V-type ATPases generate a proton-gradient by hydrolyzing ATP and are involved in acidification of intracellular compartments of the endocytotic and exocytotic pathway (for review see ref. 43, 44) . The crude membrane preparations we used contain plasma membranes as well as intracellular organelles, including acidic vesicular structures which could be responsible for the MRP1-independent uptake of cations. The macrolide antibiotic bafilomycin A 1 (Baf) is known to function as a specific inhibitor for V-type ATPases. 45 Addition of Baf blocked ATPstimulated uptake of the cations into GLC 4 Experiments with MRP1-transfected cells showed that depletion of GSH results in a complete reversal of resistance to vinca alkaloids and anthracyclines. 16 Furthermore, MRP1 mediates vincristine transport only in the presence of GSH, 13 this study). Reducing agents such as 2-mercaptoethanol, dithiothreitol and L-cysteine, have been tested but none of these could increase uptake of [ 3 H]vincristine in membrane vesicles from MRP1 transfected cells 13 indicating that it is not the reducing capacity of GSH that is responsible for this effect. GSH itself seems to play an essential role in MRP1-mediated transport of hydrophobic drugs and our findings support this. In this study we show that in the presence of physiological concentrations of GSH, the hydrophobic basic drug daunorubicin is transported by MRP1 in an ATP-dependent manner. The rate of MRP1-mediated daunorubicin transport is dependent on the concentration of GSH. This implies that changes in the intracellular GSH concentration will have a marked effect on the MRP1-mediated daunorubicin transport from drug resistant cells.
The specificity of MRP1-mediated cation transport, in particular of daunorubicin, was demonstrated by the MRP1-specific mAb QCRL-3 11, 13 and by MK571 inhibition. QCRL-3 inhibited MRP1-mediated transport of daunorubicin in the presence of GSH better than LTC 4 transport. One explanation for this effect may be a difference in binding sites for hydrophobic cations and for anions at MRP1. The competitive inhibitor MK571 inhibited MRP1-mediated GSH-dependent daunorubicin transport in a dose dependent manner with an IC 50 value of 0.4 µM. This is similar to what has been reported for LTC 4 -inhibition. 46 The difference between MRP1 inhibition by QCRL-3 and by MK571 can be explained by the difference in binding of each of these compounds to MRP1.
The mechanism by which GSH facilitates MRP1-mediated transport of hydrophobic cationic drugs has not yet been fully elucidated. There is no evidence for conjugation of GSH to drugs to which MRP1 confers resistance. 22, 16 There are indications that MRP1 mediates GSH-transport 47, 16 and may function as a co-transporter for GSH and the drug. Thus GSH may be a low affinity substrate for MRP1. From experiments using the vanadate-trapping technique it has been suggested that GSH as well as anticancer drugs directly interact with MRP1. 48 Transport of anionic MRP1-substrates such as GSH-and glucuronide-conjugates are inhibited by hydrophobic (cationic) vinca alkaloids 13, 14 and anthracyclines. 13 One hypothesis explaining these results is that MRP1 may contain two binding sites: one for hydrophobic compounds and one for hydrophilic compounds. This would allow a similar binding of GSH and the hydrophobic drug as well as binding of hydrophobic compounds conjugated to GSH, glucuronate or sulphate.
In conclusion, we showed that in addition to vincristine MRP1-mediated transport of the unmodified anticancer drug daunorubicin is dependent on GSH. APDA is not a substrate for MRP1.
